Allogene Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Allogene Therapeutics has a total shareholder equity of $461.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $586.4M and $125.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$384.86m |
Equity | US$461.37m |
Total liabilities | US$124.98m |
Total assets | US$586.35m |
Recent financial health updates
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Recent updates
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Jun 12We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
May 30Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Allogene Therapeutics: Multibagger Potential, But Terribly Risky
Jun 24Allogene: Leading The Allogeneic CAR-T Space, Again
Apr 01Allogene: Lifting Of The Clinical Hold Will Be A Major Binary
Jan 12Financial Position Analysis
Short Term Liabilities: ALLO's short term assets ($395.4M) exceed its short term liabilities ($30.9M).
Long Term Liabilities: ALLO's short term assets ($395.4M) exceed its long term liabilities ($94.1M).
Debt to Equity History and Analysis
Debt Level: ALLO is debt free.
Reducing Debt: ALLO has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALLO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALLO has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 13.2% each year.